acalabrutinib,rituximab,lisaftoclax
astrazeneca,ascentage pharmaceuticals
['acalabrutinib', 'cll', 'lisaftoclax', 'ritux']
congress | #ash22 , discussed lisaftoclax in pts with #cll and #sll. grade 3/4 neutropenia was common in monotherapy and in combination. no dlts were observed. the best response was seen in the lisa + acalabrutinib cohort, with an orr of 98% in r/r pts. 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm